SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Capital International Investors

Capital International Investors lifted its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 92.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,361,746 shares of the company's stock after buying an additional 1,136,079 shares during the quarter. Capital International Investors owned approximately 3.17% of SpringWorks Therapeutics worth $85,330,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SWTX. Barclays PLC increased its holdings in SpringWorks Therapeutics by 60.4% in the third quarter. Barclays PLC now owns 155,676 shares of the company's stock valued at $4,987,000 after buying an additional 58,645 shares in the last quarter. Geode Capital Management LLC grew its holdings in SpringWorks Therapeutics by 7.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,670,247 shares of the company's stock valued at $53,526,000 after buying an additional 109,189 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of SpringWorks Therapeutics in the 3rd quarter worth $3,226,000. Principal Financial Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 102.5% during the 3rd quarter. Principal Financial Group Inc. now owns 918,445 shares of the company's stock worth $29,427,000 after acquiring an additional 464,903 shares during the period. Finally, Park Avenue Securities LLC acquired a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at about $203,000.

SpringWorks Therapeutics Trading Down 1.0 %

Shares of NASDAQ SWTX traded down $0.46 during midday trading on Friday, reaching $44.47. 4,428,538 shares of the company were exchanged, compared to its average volume of 1,452,274. The stock has a market cap of $3.33 billion, a P/E ratio of -12.78 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The stock has a fifty day simple moving average of $46.43 and a 200 day simple moving average of $40.41.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $61.55 million during the quarter, compared to analysts' expectations of $60.53 million. As a group, analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SWTX. Wedbush restated an "outperform" rating and set a $81.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Guggenheim reduced their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Evercore ISI lifted their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, HC Wainwright reissued a "buy" rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Buy" and a consensus target price of $73.20.

Insider Activity at SpringWorks Therapeutics

In related news, insider Daniel Pichl sold 29,750 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $54.36, for a total value of $1,617,210.00. Following the completion of the sale, the insider now owns 50,762 shares in the company, valued at $2,759,422.32. This trade represents a 36.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. The trade was a 1.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,766 shares of company stock worth $24,402,956 in the last three months. Insiders own 7.83% of the company's stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.